3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
4
Recruiting
3
Completed
2
Withdrawn
1
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
17
Melanoma
5
Triple Negative Breast Neoplasms
4
Small Cell Lung Carcinoma
4
Neoplasms
4
Carcinoma, Renal Cell
4
Carcinoma, Hepatocellular
4
Breast Neoplasms
4
Urinary Bladder Neoplasms
3
Stomach Neoplasms
2
Mesothelioma, Malignant
2
Head and Neck Neoplasms
2
Gastrointestinal Neoplasms
2
Carcinoma, Merkel Cell
2
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Small Cell Lung Cancer Recurrent
1
Safety Issues
1
Recurrent Liver Cancer After Liver Transplantation
1
Recurrence
1
Radiation Pneumonitis
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Neoplasm Metastasis
1
Lymphoma
1
Lung Neoplasms
1
Locally Advanced or Metastatic Solid Tumors
1
Liver Neoplasms
1
Kidney Neoplasms
1
Hodgkin Disease
1
Interventions
Cyclophosphamide
17
fludarabine
13
Dexamethasone
12
Cisplatin
12
Rituximab
10
Gemcitabine
9
Paclitaxel
8
Bendamustine Hydrochloride
8
Lenalidomide
7
Decitabine
7
Cytarabine
7
Carboplatin
7
fludarabine phosphate
6
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
6
Etoposide
6
Bortezomib
6
Radiotherapy
5
Injections
5
Azacitidine
5
camrelizumab
4
apatinib
4
Valproic Acid
4
Thalidomide
4
Procarbazine
4
Oxaliplatin
4
Drug Therapy
4
Bevacizumab
4
Antilymphocyte Serum
4
venetoclax
3
pomalidomide
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Recurrence
×
atezolizumab
×
Clear all
NCT04739670
2024-03-01
BELLA
Peter MacCallum Cancer Centre, Australia
Phase 2
Unknown
31 enrolled